drugset / Trial / NCT02576457
Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether BMS-936559 is safe and has the desired pharmacologic activity in patients who have severe sepsis.
Timeline
- Start
- 2015-12-02
- Primary completion
- 2017-03-15
- Completion
- 2017-03-15
Outcome
Outcome not reported
Stopped (Business): “Business Objectives Have Changed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-936559 | Monoclonal antibody | 10 mg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 30 mg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 100 mg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 300 mg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 900 mg | Intravenous |